- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%. - The analysis also ...
PALO ALTO, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Today Alpha Medical, the company rebuilding women’s healthcare, announced Alpha Membership, a new service that expands on their seamless online ...
Alpha Tau Medical (NASDAQ:DRTS) recently reported its Q3 2025 results, providing updates on ongoing clinical studies, regulatory progress, and manufacturing readiness - developments that indicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback